A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Name: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Creator: Vivli
Published: 2025-11-25 12:22:04
License: 暂无描述

DataCite Commons2025-11-25 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00011971/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

提供机构：

Vivli

创建时间：

2025-11-24